FamiCord and Vita 34 Vice president speaks on cord blood banking at Advanced Therapies conference in London

Tomasz Baran, MD, MBA, Vice President of FamiCord Group and Vita 34, shared his expertise on the evolving field of cord blood banking at the prestigious Advanced Therapies Conference in London. During his presentation, Dr. Baran discussed the pivotal role of cord blood in regenerative medicine and the exciting developments in advanced therapies, highlighting FamiCord Group’s leadership in the industry in Europe. His insights emphasized how the integration of cutting-edge biotechnology and stem cell banking is shaping the future of personalized treatments and cell-based therapies.

The Advanced Therapies Congress is Europe’s largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and start-up companies, researchers, clinicians, academics, HTAs, payers and regulators.  ItT is based, each year, in ExCELL Center in London, United Kingdom.

Tomasz Baran was one of speakers in a session dedicated to cord blood stem cells at the Advanced Therapies Conference in London, moderated by Professor Joanne Kurtzberg, President of the Cord Blood Association (CBA) and a pioneer in the application of cord blood stem cells from Duke University in the USA.

Main topic of the speech was to present banked cord blood as viable therapeutic option. T.Baran focused on the complexities of cord blood banking, highlighting the significant differences in European legislation. He explained that while cord blood stem cells are a standard treatment in haematology across Europe, their use in neurology is classified as an Advanced Therapy Medicinal Product (ATMP), which plays a crucial role in parents’ decisions when selecting a bank for cord blood preservation. By choosing a bank from the FamiCord Group, parents can feel confident knowing that FamiCord has two experienced CDMO manufacturing facilities under its roof, ensuring the highest production standards. If needed, FamiCord is capable of producing ATMPs for its clients, providing comprehensive support in the field of cell-based therapies- comments T. Baran.